Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab리툭시맙으로 치료받은 다발성 경화증 환자에서 SARS-CoV-2 백신 접종에 대한 혈청학적 반응과 관련된 요인Article Published on 2022-05-022022-09-12 Journal: JAMA Network Open [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] accumulated age analyzed angiotensin-converting enzyme 2 Anti-RBD IgG anti-receptor-binding domain Anti-spike anti-Spike IgG antibodies antibody B cells B-cell binding antibody CD19+ CD4+ T-cell CD8+ T-cell cellular response cohort study conducted COVID-19 infection Cutoff cutoff value Diagnosis disease dose Factor first vaccination Follow-up greater identify IgG IgG antibodies Immunoglobulin interferon gamma median monoclonal antibody Multiple multiple sclerosis Neutralizing outcome outcomes Patient patients evaluated peptide pool positive response positive test result proportion prospective cohort study quantitation RBD reached response rituximab SARS-CoV-2 sclerosis serological response spot-forming unit T-cell Response the median Treatment university hospital vaccination vaccine response Vaccines were assessed were measured women [DOI] 10.1001/jamanetworkopen.2022.11497 PMC 바로가기 [Article Type] Article
Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccinesBNT162b2 및 CoronaVac 백신으로 회복된 COVID-19 환자 중 Omicron 변이체에 대한 혈청 중화 활성 증가Article Published on 2022-05-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Analysis Antibody test Beta Beta variant BNT162b2 characteristic CoronaVac country COVID-19 Cutoff Delta delta variant detectable determine dose evade geometric geometric mean greater Immunity Inactivated vaccine individual induce Infection Live virus Michael mRNA vaccine NAb titer Neutralizing activity neutralizing antibody of BNT162b2 omicron Omicron variant prospective cohort study Protein receiver receiver operating characteristic Receptor binding recipient recovered COVID-19 patient Recovered COVID-19 patients Reinfection Richard risk SARS-CoV-2 Sensitivity and specificity seropositive serum Serum neutralizing antibody significantly higher spike Spike protein Spike protein receptor binding domain statistically subgroup analysis surrogate Surrogate neutralizing antibody test vaccination Vaccine variant variants virus with COVID-19 [DOI] 10.1016/j.ebiom.2022.103986 PMC 바로가기 [Article Type] Article
Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab나탈리주맙으로 치료받은 다발성 경화증 환자에서 BNT162b2 mRNA COVID-19 백신에 대한 6개월 체액 반응Article Published on 2022-05-012022-09-11 Journal: Neurological Sciences [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] A significant reduction age All participants BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine booster dose booster doses both group both groups clinician collected comparable COVID-19 COVID-19 vaccination COVID-19 vaccine Cutoff develop DiaSorin first dose healthy humoral humoral immune response Humoral response IgG IgG antibodies IgG antibody immune response investigated LIAISON limit maintain mRNA mRNA vaccine Multiple multiple sclerosis Natalizumab of BNT162b2 Participants Patient positive positive IgG antibodies SARS-CoV-2 SARS-CoV-2 IgG antibodies SARS-CoV-2 IgG antibody SARS-CoV-2 spike protein SARS-CoV-2 vaccine serum sample serum samples Spike protein treated Vaccine [DOI] 10.1007/s10072-022-05940-0 PMC 바로가기 [Article Type] Article
Low phase angle is associated with 60-day mortality in critically ill patients with COVID-19낮은 위상각은 COVID-19 중환자의 60일 사망률과 관련이 있습니다.Article Published on 2022-05-012022-09-11 Journal: JPEN. Journal of parenteral and enteral nutrition [Category] COVID19(2023년), SARS, 치료기술, [키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus Admission Analysis association bioelectrical impedance Bioelectrical Impedance Analysis biological marker body composition body water clinical outcomes coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Critically ill Critically ill patient critically ill patients Cutoff death Extracellular female hazard ratio Hospital stay increased risk intensive care intensive care unit admission Kaplan-Meier curves Linear regression model male Malnutrition mechanical ventilation mechanically ventilated patient mechanically ventilated patients Mortality mortality risk nutrition risk nutrition status Odds ratio on mechanical ventilation parameter Pathologies Patient Phase angle predictor prospective cohort risk Risk assessment SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significantly increased survival analysis variable was performed water were used with COVID-19 [DOI] 10.1002/jpen.2236 PMC 바로가기 [Article Type] Article
Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients-A Prospective Study신장 이식 환자의 3차 접종 BNT162b2 COVID-19 백신에 대한 면역 반응-전향적 연구Article Published on 2022-04-212022-09-12 Journal: Transplant International [Category] COVID19(2023년), SARS, 진단, [키워드] 95% confidence interval anti-spike antibody antibody Antibody Response BNT162b2 cellular cellular response conducted control group controls COVID-19 COVID-19 vaccine Cutoff demonstrated dose evaluate evaluated healthcare humoral identify immune response Immunosuppression immunosuppression reduction kidney transplant recipient kidney transplant recipients kidney transplant recipients. log mRNA vaccine Multivariate analysis Odds ratio Participants Primary outcome Prospective Prospective Study reduction remained response Result SARS-CoV-2 second dose seronegative subset T-cell Response Transplant vaccination Vaccine vaccine dose variable [DOI] 10.3389/ti.2022.10204 PMC 바로가기 [Article Type] Article
Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in IndiaClinical Trial Published on 2022-04-022022-10-05 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 임상, [키워드] 1:1 95% CI Administered adverse event Analysis assessment assigned baseline Biotechnology clinical clinical trial comorbid conditions conducted COVID-19 criteria Cutoff death Department DNA dose double-blind Efficacy efficacy analysis eligible enrolled Government of India Gujarat identify immunogenic India individual injection interim analysis investigators multicentre Occurrence Older outcome assessor participant per-protocol population Phase 3 phase 3 trial Placebo placebo group placebo-controlled placebo-controlled study Primary outcome randomisation randomised Randomly receive Registered registry reported Safe safety population SARS-CoV-2 SARS-CoV-2 vaccine screened symptomatic the placebo group Tolerability Treatment treatment group Trial Vaccine was done was used [DOI] 10.1016/S0140-6736(22)00151-9 PMC 바로가기 [Article Type] Clinical Trial
Determinants of Immune Response to Anti-SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients: A Prospective Cohort Study신장 이식 수혜자의 Anti-SARS-CoV-2 mRNA 백신에 대한 면역 반응의 결정 요인: 전향적 코호트 연구Article Published on 2022-04-012022-09-12 Journal: Transplantation [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 95% confidence interval acute respiratory syndrome affecting analyzed antibody contrary coronavirus coronavirus disease Cutoff depleting determinant Effectiveness epitope evaluated exhibited Factor humoral immune response independent infected with SARS-CoV-2 interferon gamma kidney transplant recipient mRNA mRNA vaccines mycophenolate Odds ratio Patient Prospective prospective cohort study response S1 and S2 SARS-CoV-2 sensitivity Seroconversion shown significantly more Specific T-cell response specificity Spike protein subset subunit sustained tested the interferon therapy Transplant vaccination Vaccine [DOI] 10.1097/TP.0000000000004044 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials건강한 성인에서 코로나백 3차 접종의 면역원성 및 안전성, 2회 접종 일정의 면역 지속성: 2건의 단일 센터, 이중 맹검, 무작위, 위약 대조 임상 2상 임상 시험의 중간 결과Clinical Trial Published on 2022-04-012022-09-12 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 1:1 95% CI Abstract Administered Adverse reaction analysed antibody Antibody titre assigned Beijing booster dose China clinical trial clinical trials Cohort cohorts Concentration CoronaVac country Cutoff declined development dose doses double-blind eligible foundation GenBank accession number generate geometric geometric mean titre GMIs GMT GMTs groups healthy immune memory immune persistence immune response immunogenicity Inactivated vaccine increase increase in injection Jiangsu material natural neutralising antibody neutralising antibody titre Older outcome participant per-protocol population phase 2 trial Placebo placebo group placebo-controlled positive Program protocol amendment randomised Randomly recalled receive Registered reported resulting SARS-CoV-2 Science second dose Serious Adverse Event seropositive severity significantly increased technology threshold translation Trial vaccination vaccination against COVID-19 vaccination schedule Vaccine virus strain [DOI] 10.1016/S1473-3099(21)00681-2 PMC 바로가기 [Article Type] Clinical Trial
Definition of the Immune Parameters Related to COVID-19 SeverityCOVID-19 심각도와 관련된 면역 매개변수의 정의Article Published on 2022-03-182022-09-11 Journal: Frontiers in Immunology [Category] SARS, 치료기술, [키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered Admission allocation among others Analysis analyzed Blood blood cell blood cell count caused Cell changes in clinical decision Clinical management Cohort coronavirus COVID-19 COVID-19 outcome COVID-19 patients Critical Cutoff defined Definition described disease disease severity fluctuations for inclusion granulocyte groups highlight Hospitalization hospitalized COVID-19 patient hospitalized COVID-19 patients immunological immunological changes intensive care intensive care unit admission Laboratory Laboratory test lymphocyte Medical resources Mild moderate non-survivor offer outcome oxygen oxygen support Oxygen therapy parameter Patient Peripheral blood peripheral blood cell peripheral blood cells predict Predictive proof recorded ROC Curve sensitivity separated severe acute respiratory syndrome Coronavirus severity Severity of disease Severity Score specificity survival survivor symptomatic the disease therapy Triage [DOI] 10.3389/fimmu.2022.850846 PMC 바로가기 [Article Type] Article
Fear among Syrians: A Proposed Cutoff Score for the Arabic Fear of COVID-19 ScaleResearch Article Published on 2022-03-112022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, SARS, [키워드] Analysis Anxiety Arabic can be used Community correlation COVID-19 COVID-19 pandemic Cutoff cutoff point disorder extreme fear Health internal consistency measure participant Population psychological health questionnaire receiver operating characteristic scale socio-demographic information stability the patient to define was used [DOI] 10.1371/journal.pone.0264257 PMC 바로가기 [Article Type] Research Article